IL18 and colitis: Recently, it was discovered that treatment with exogenous BHB mitigated experimental colitis in rat model colitis through the inhibition of NLRP3 inflammasome activation, resulting in a low release of IL-1β and IL-18 and attenuated intestinal epithelial damage, as well as in the restoration of the intestinal epithelial barrier.